This HTML5 document contains 67 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n9http://linked.opendata.cz/resource/drugbank/drug/DB01393/identifier/pharmgkb/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01393/identifier/wikipedia/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/AHFS/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01393/identifier/bindingdb/
n23http://linked.opendata.cz/resource/drugbank/drug/DB01393/identifier/pdb/
n16http://linked.opendata.cz/resource/mesh/concept/
n24http://linked.opendata.cz/resource/drugbank/drug/DB01393/identifier/pubchem-compound/
n17http://linked.opendata.cz/resource/drugbank/mixture/
n26http://linked.opendata.cz/resource/drugbank/drug/DB01393/identifier/kegg-drug/
n5http://linked.opendata.cz/resource/drugbank/drug/DB01393/identifier/pubchem-substance/
n4http://linked.opendata.cz/resource/drugbank/drug/DB01393/identifier/drugbank/
n19http://bio2rdf.org/drugbank:
n25http://linked.opendata.cz/resource/drugbank/drug/DB01393/identifier/iuphar/
n27http://linked.opendata.cz/resource/drugbank/drug/DB01393/identifier/guide-to-pharmacology/
admshttp://www.w3.org/ns/adms#
n21http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n14http://linked.opendata.cz/resource/drugbank/medicinal-product/
n15http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n6http://linked.opendata.cz/ontology/drugbank/
n28http://linked.opendata.cz/resource/drugbank/drug/DB01393/identifier/chemspider/
n7http://linked.opendata.cz/resource/drugbank/property/
n22http://linked.opendata.cz/resource/drugbank/drug/DB01393/identifier/chebi/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/atc/
n10http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01393
rdf:type
n6:Drug
n6:description
Antilipemic agent that lowers cholesterol and triglycerides. It decreases low density lipoproteins and increases high density lipoproteins. [PubChem]
n6:generalReferences
# "Link":http://www.medsafe.govt.nz/profs/Datasheet/b/Bezaliptab.htm # : Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000 Jul 4;102(1):21-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10880410 # Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S: Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med. 2005 May 23;165(10):1154-60. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15911729 # Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S: Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation. 2004 May 11;109(18):2197-202. Epub 2004 May 3. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15123532 # Tenenbaum A, Fisman EZ, Boyko V, Benderly M, Tanne D, Haim M, Matas Z, Motro M, Behar S: Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med. 2006 Apr 10;166(7):737-41. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16606809
n6:group
approved
n6:halfLife
1-2 hours
n6:indication
For the treatment of primary hyperlipidaemia types IIa, IIb, III, IV and V (Fredrickson classification) corresponding to groups I, II and III of the European Atherosclerosis Society guidelines - when diet alone or improvements in lifestyle such as increased exercise or weight reduction do not lead to an adequate response. Also for the treatment of secondary hyperlipidaemias, e.g. severe hypertriglyceridemias, when sufficient improvement does not occur after correction of the underlying disorder (e.g. diabetes mellitus).
owl:sameAs
n19:DB01393 n21:DB01393
dcterms:title
Bezafibrate
adms:identifier
n4:DB01393 n5:46509188 n9:PA162364313 n13:Bezafibrate n20:28701 n22:47612 n23:PEM n24:39042 n25:2668 n26:D01366 n27:2668 n28:35728
n6:mechanismOfAction
Like the other fibrates, bezafibrate is an agonist of PPARα; some studies suggest it may have some activity on PPARγ and PPARδ as well.
n6:synonym
2-(P-(2-(P-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid Bezatol sr (tn) Bezalip Befizal Cedur Bezafibrato Bezafibratum Bezafibrat
n10:hasAHFSCode
n12:24-06-06
n6:mixture
n17:271B4504-363D-11E5-9242-09173F13E4C5
n6:proteinBinding
94-96% of bezafibrate is bound to protein in human serum.
n15:hasConcept
n16:M0002449
n6:IUPAC-Name
n7:271B450A-363D-11E5-9242-09173F13E4C5
n6:InChI
n7:271B4510-363D-11E5-9242-09173F13E4C5
n6:Molecular-Formula
n7:271B450F-363D-11E5-9242-09173F13E4C5
n6:Molecular-Weight
n7:271B450C-363D-11E5-9242-09173F13E4C5
n6:Monoisotopic-Weight
n7:271B450D-363D-11E5-9242-09173F13E4C5
n6:SMILES
n7:271B450E-363D-11E5-9242-09173F13E4C5
n6:Water-Solubility
n7:271B4508-363D-11E5-9242-09173F13E4C5
n6:logP
n7:271B4506-363D-11E5-9242-09173F13E4C5 n7:271B4509-363D-11E5-9242-09173F13E4C5
n6:logS
n7:271B4507-363D-11E5-9242-09173F13E4C5
n10:hasATCCode
n11:C10AB02
n6:H-Bond-Acceptor-Count
n7:271B4516-363D-11E5-9242-09173F13E4C5
n6:H-Bond-Donor-Count
n7:271B4517-363D-11E5-9242-09173F13E4C5
n6:InChIKey
n7:271B4511-363D-11E5-9242-09173F13E4C5
n6:Polar-Surface-Area--PSA-
n7:271B4512-363D-11E5-9242-09173F13E4C5
n6:Polarizability
n7:271B4514-363D-11E5-9242-09173F13E4C5
n6:Refractivity
n7:271B4513-363D-11E5-9242-09173F13E4C5
n6:Rotatable-Bond-Count
n7:271B4515-363D-11E5-9242-09173F13E4C5
n6:absorption
Bezafibrate is almost completely absorbed after oral administration. The relative bioavailability of bezafibrate retard compared to the standard form is about 70%.
n6:affectedOrganism
Humans and other mammals
n6:casRegistryNumber
41859-67-0
n6:category
n6:containedIn
n14:271B4505-363D-11E5-9242-09173F13E4C5
n6:Bioavailability
n7:271B451C-363D-11E5-9242-09173F13E4C5
n6:Ghose-Filter
n7:271B451E-363D-11E5-9242-09173F13E4C5
n6:MDDR-Like-Rule
n7:271B451F-363D-11E5-9242-09173F13E4C5
n6:Melting-Point
n7:271B4520-363D-11E5-9242-09173F13E4C5
n6:Number-of-Rings
n7:271B451B-363D-11E5-9242-09173F13E4C5
n6:Physiological-Charge
n7:271B451A-363D-11E5-9242-09173F13E4C5
n6:Rule-of-Five
n7:271B451D-363D-11E5-9242-09173F13E4C5
n6:Traditional-IUPAC-Name
n7:271B450B-363D-11E5-9242-09173F13E4C5
n6:pKa--strongest-acidic-
n7:271B4518-363D-11E5-9242-09173F13E4C5
n6:pKa--strongest-basic-
n7:271B4519-363D-11E5-9242-09173F13E4C5